ABSTRACT
Sublingual immunotherapy (SLIT) is an efficacious and safe alternative to subcutaneous immunotherapy (SCIT). During the last three decades, SLIT has been widely used in many countries, primarily in central and southern Europe, where more than 50% of the current population of patients receiving specific immunotherapy are on SLIT (1).
